GlassScriptPhysician profile
Kenneth W Jackson
NPI 1972510352
$1,904.96
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $1,044 · 2023: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $253.14 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $197.63 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $115.12 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $95.28 | 2021-2022 | |
| Urovant Sciences INC | $80.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.40 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $62.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $55.91 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $54.62 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $47.65 | 2021-2023 | Xarelto |
| Lilly USA, LLC | $46.20 | 2021-2023 | Trulicity, Basaglar, Humalog |
| Sanofi-Aventis U.S. LLC | $44.33 | 2021-2022 | |
| Abbvie INC. | $43.63 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41.59 | 2021-2022 | |
| Pfizer INC. | $37.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.91 | 2022 | |
| Alkermes, INC. | $27.35 | 2023 | Lybalvi |
| Abbott Laboratories | $21.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.54 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.23 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.98 | 2021 | |
| Dexcom, INC. | $19.81 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.66 | 2021 | |
| Astellas Pharma US INC | $17.72 | 2021 | |
| Eisai INC. | $16.95 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.33 | 2021 | |
| Exact Sciences Corporation | $15.91 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.